News First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Home > First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line 16 June 2016 First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine in 2016 To read the press release
